EC's non-decision keeps Glybera MAA alive

Amsterdam Molecular Therapeutics Holding N.V. (Euronext:AMT) said the European Commission asked for more information from EMA's CHMP before it can make a final decision on an MAA for Glybera to treat lipoprotein lipase (LPL) deficiency. According to the company, the EC could not reach a decision at a Jan. 22 meeting on the application, which received two negative opinions from CHMP last year. ...